Table 1.
Patient characteristics.
| Characteristics | Total population, 91, n (%) | Filled relugolix, 71, n (%) |
|---|---|---|
| Race | ||
| White-non-Hispanic | 66 (73) | 53 (75) |
| Hispanic/Latino | 6 (7) | 5 (7) |
| Black | 3 (3) | 3 (4) |
| Asian | 9 (10) | 5 (7) |
| American Indian/native American | 1 (1) | 1 (1) |
| Not reported | 6 (7) | 4 (6) |
| Insurance | ||
| Medicare | 59 (65) | 43 (61) |
| Private | 25 (27) | 21 (30) |
| Medi-Cal | 5 (5) | 5 (7) |
| Other | 2 (2) | 2 (3) |
| Age | ||
| <65 | 21 (23) | 18 (25) |
| ≥65, <75 | 49 (54) | 39 (55) |
| ≥75 | 21 (23) | 14 (20) |
| Cardiac risk factors | ||
| Coronary disease | 31 (34) | 23 (32) |
| Diabetes | 16 (18) | 14 (20) |
| Hypertension | 57 (63) | 41 (58) |
| Hyperlipidemia | 46 (51) | 33 (46) |
| Former smoker | 19 (21) | 16 (23) |
| Active smoker | 2 (2) | 2 (3) |
| BMI ≥30 | 25 (27) | 21 (30) |
| Indication | ||
| Adjuvant | 22 (24) | 18 (25) |
| BCR | 37 (41) | 27 (38) |
| mCSPC | 24 (26) | 19 (27) |
| Mcrpc | 8 (9) | 7 (10) |
| Castration history | ||
| Castration naïve | 36 (40) | 31 (44) |
| Previously castrated | 27 (30) | 21 (30) |
| Switch degarelix | 11 (12) | 6 (8) |
| Switch leuprolide | 17 (19) | 13 (18) |
| Any switch | 28 (31) | 19 (27) |
| Follow-up | Median: 5 months | Range: 1-12 months |
Abbreviations: BCR, biochemical recurrence; BMI, body mass index; mCSPC, metastatic disease-castration sensitive; mCRPC, metastatic disease-castration resistant.